Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer
Fifty1 Labs (OTC:FITY) named Dr. Joel Gagnier as Chief Science Officer on October 9, 2025, bolstering its evidence-based AI efforts in personalized wellness, musculoskeletal health, pain management, and perioperative outcomes.
Dr. Gagnier brings academic and industry credentials: ND, MSc, PhD, a postdoctoral fellowship, an associate professorship at Western University, leadership in clinical epidemiology education, >CAD 20 million in secured research funding, >210 peer-reviewed papers, and >300 international lectures. His expertise covers clinical trial methodology, PROMs, meta-analysis, AI/ML integration, regulatory submissions, and product development—skills positioned to strengthen research rigor, regulatory readiness, and investor/partner confidence.
Fifty1 Labs (OTC:FITY) ha nominato il dottor Joel Gagnier come Chief Science Officer il 9 ottobre 2025, rafforzando i suoi sforzi basati sull'evidenza di AI per il benessere personalizzato, la salute muscoloscheletrica, la gestione del dolore e gli esiti perioperatori.
Il Dottor Gagnier porta credenziali accademiche e industriali: ND, MSc, PhD, un assegno di post-dottorato, professore associato presso Western University, leadership nell'educazione di epidemiologia clinica, >CAD 20 milioni di CAD in finanziamenti per ricerche assicurati, >210 articoli peer-reviewed, e >300 conferenze internazionali. La sua expertise copre metodologia degli studi clinici, PROMs, meta-analisi, integrazione IA/ML, sottomissioni normative e sviluppo di prodotti—abilità mirate a rafforzare la rigorosità della ricerca, la prontezza regolatoria e la fiducia di investitori/partner.
Fifty1 Labs (OTC:FITY) nombró al Dr. Joel Gagnier como Chief Science Officer el 9 de octubre de 2025, fortaleciendo sus esfuerzos de IA basados en evidencia en el bienestar personalizado, la salud musculoesquelética, el manejo del dolor y los resultados perioperatorios.
El Dr. Gagnier aporta credenciales académicas e industriales: ND, MSc, PhD, una beca postdoctoral, una cátedra de asociado en Western University, liderazgo en educación de epidemiología clínica, >CAD 20 millones en financiamiento de investigación asegurado, >210 artículos revisados por pares y >300 conferencias internacionales. Su experiencia abarca metodología de ensayos clínicos, PROMs, meta-análisis, integración de IA/ML, presentaciones regulatorias y desarrollo de productos—habilidades orientadas a fortalecer el rigor de la investigación, la preparación regulatoria y la confianza de inversores/socios.
Fifty1 Labs (OTC:FITY)가 Dr. Joel Gagnier를 2025년 10월 9일에 Chief Science Officer로 임명하여 개인화된 웰빙, 근골격 건강, 통증 관리 및 수술 전후 결과에 대한 근거 기반 AI 노력을 강화합니다.
Gagnier 박사는 학계와 산업계의 자격을 갖추고 있습니다: ND, MSc, PhD, 박사후 연구원, Western University의 부교수, 임상 역학 교육 리더십, CAD 2천만 달러 이상의 연구 자금 확보, >210편의 동료 심사 논문, 그리고 >300회의 국제 강연. 그의 전문 분야는 임상시험 방법론, PROMs, 메타분석, AI/ML 통합, 규제 제출 및 제품 개발이며, 연구의 엄격성, 규제 준비 및 투자자/파트너의 신뢰를 강화할 수 있는 역량을 제공합니다.
Fifty1 Labs (OTC:FITY) a nommé le Dr Joel Gagnier au poste de Chief Science Officer le 9 octobre 2025, renforçant ses efforts d'IA fondés sur des preuves dans le bien-être personnalisé, la santé musculo-squelettique, la gestion de la douleur et les résultats périopératoires.
Le Dr Gagnier apporte des accréditations académiques et industrielles : ND, MSc, PhD, une bourse postdoctorale, professeur associé à l'Université Western, leadership dans l'éducation en epidemiologie clinique, >CAD 20 millions de financement de recherche assuré, >210 articles évalués par des pairs et >300 conférences internationales. Son expertise couvre la méthodologie des essais cliniques, les PROMs, la méta-analyse, l'intégration IA/ML, les soumissions réglementaires et le développement de produits — des compétences destinées à renforcer la rigueur de la recherche, la préparation réglementaire et la confiance des investisseurs/partenaires.
Fifty1 Labs (OTC:FITY) hat Dr. Joel Gagnier am 9. Oktober 2025 zum Chief Science Officer ernannt, um seine evidenzbasierte KI-Bemühungen in personalisiertem Wohlbefinden, muskuloskelettaler Gesundheit, Schmerzmanagement und perioperativen Ergebnissen zu stärken.
Dr. Gagnier bringt akademische und industrielle Referenzen mit: ND, MSc, PhD, ein Postdoktorandenstipendium, ein assoziierter Professor an der Western University, Führung in der Lehre der klinischen Epidemiologie, >CAD 20 Millionen an gesicherten Forschungsfinanzierungen, >210 peer‑reviewed papers und >300 internationale Vorträge. Seine Expertise deckt Methoden klinischer Studien, PROMs, Metaanalysen, AI/ML-Integration, regulatorische Einreichungen und Produktentwicklung ab—Fähigkeiten, die darauf abzielen, Forschungsmessbarkeit, regulatorische Bereitschaft und Vertrauen von Investoren/Partnern zu stärken.
Fifty1 Labs (OTC:FITY) عيّنت الدكتور Joel Gagnier لمنصب Chief Science Officer في 9 أكتوبر 2025، مما يعزز جهوده القائمة على الأدلة في الذكاء الاصطناعي المخصص للصحة العامة والرفاهية، والصحة العضلية الهيكلية، وإدارة الألم، ونتائج ما قبل وبعد الجراحة.
يجلب الدكتور گاجنييه مؤهلات أكاديمية وصناعية: ND، MSc، PhD، زمالة ما بعد الدكتوراة، وأستاذ مشارك في جامعة Western، وقيادة في تعليم علم الأوبئة السريرية، وتمويل بحثي مُؤمَّن بـ CAD > 20 مليون، وأكثر من >210 ورقة محكمة ومشاركة في >300 محاضرة دولية. تغطي خبرته منهجية التجارب السريرية، PROMs، التحليلات التلوية، دمج AI/ML، التقديمات التنظيمية وتطوير المنتجات—مهارات تعزز صرامة البحث، والاستعداد التنظيمي، وثقة المستثمرين/الشركاء.
Fifty1 Labs (OTC:FITY) 任命 Joel Gagnier 博士为首席科学官，时间定于2025年10月9日，以加强其在个性化健康、肌骨健康、疼痛管理及围手术期结局方面的证据驱动人工智能工作。
Gagnier 博士具备学术与产业背景：ND、MSc、PhD、博士后研究员、西方法院大学的副教授、临床流行病学教育的领导者、>CAD 2000万美元及以上的研究资助、>210篇同行评审论文，及>300场国际讲座。其专长覆盖临床试验方法、PROMs、元分析、AI/ML整合、监管申报与产品开发——这些技能将提升研究的严格性、监管准备以及投资者/合作伙伴的信心。
- Appointed experienced CSO with >CAD 20 million in secured research funding
- CSO authored >210 peer-reviewed papers
- CSO delivered >300 international lectures and workshops
- Expertise in trial methods and PROMs improves research rigor and regulatory readiness
- None.
Pioneering Evidence-Based AI Innovation in Personalized Wellness and Health Research
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs' commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.
Dr. Gagnier brings highly credentialed academic and clinical epidemiology leadership to Fifty1 AI Labs. With a Doctor of Naturopathic Medicine (ND) from the Canadian College of Naturopathic Medicine, an MSc and PhD in Clinical Epidemiology & Biostatistics from the University of Toronto, and a post-doctoral fellowship in Epidemiologic Methods at the University of Michigan, he currently serves as Associate Professor in both Epidemiology & Biostatistics and Surgery at Western University's Schulich School of Medicine & Dentistry. As Field Leader of the Clinical Epidemiology & Research Management master's program, Dr. Gagnier has trained the next generation of health researchers. His formal, advanced training establishes strong scientific legitimacy for Fifty1AI Labs, signaling to investors and partners that the company is dedicated to high-quality, evidence-based health research rather than superficial wellness marketing.
A recognized expert in clinical trial methodology, systematic reviews, meta-analyses, outcome measurement, and reporting standards—particularly for patient-reported outcome measures (PROMs), bias assessment, and measurement scale validation—Dr. Gagnier has focused his research on enhancing the properties of health outcome scales, reducing bias in PROMs, and improving trial reporting consistency. This expertise ensures that Fifty1 AI Labs' data and insights are replicable, transparent, and rigorous, providing a key differentiator in risk mitigation, regulatory acceptance, and credibility with customers and collaborators.
Dr. Gagnier's strong domain experience aligns seamlessly with Fifty1 AI Labs' focus areas, including musculoskeletal conditions, perioperative outcomes (such as pain and function), sports medicine, surgical safety, clinical care outcomes, and peptides. His research program emphasizes multi-centered clinical studies and the application of AI and machine learning to trial design and implementation. Having overseen laboratories, supervised students, fellows, and residents, and published extensively in these fields, Dr. Gagnier positions Fifty1 AI Labs to capitalize on large-market opportunities in pain relief, mobility, injury recovery, and personalized interventions, leveraging computational methods for faster, smarter innovation and competitive advantage.
With a proven track record of securing large-scale funding—over CAD
Dr. Gagnier's decades of industry and advisory experience further strengthen his role, including serving as Senior Science Officer at Jamieson Laboratories Ltd., Chief Scientific Officer at Second Life Global, and scientific consultant to global pharma leaders like Sanofi, Johnson & Johnson, Prollenium Medical Technologies, and London Pharmaceutical Sciences Inc. His background in natural health products, herbal medicine research, evidence-based formulation, regulatory submissions (e.g., for CBD and related products), quality control (GMP), and product development addresses investor concerns around regulatory scrutiny and market viability. This real-world expertise ensures Fifty1 AI Labs' innovations are compliant, commercially scalable, and grounded in safety and efficacy.
Committed to innovation in personalized wellness, Dr. Gagnier explores heterogeneity of treatment effects (how individuals respond differently to interventions), reproducibility, transparency, and outcome precision. His work integrates AI/ML for nuanced, precise evidence generation, improving measurement tool validity, reliability, and responsiveness. This approach enables Fifty1 AI Labs to deliver scalable yet personalized solutions that withstand scrutiny, support ethical standards, and command premium market positioning through stronger trust from partners and purchasers.
"We are thrilled to welcome Dr. Joel Gagnier to Fifty1 AI Labs as our Chief Science Officer," said Paul Arora, CEO of Fifty1 AI Labs Inc. "Joel's unparalleled blend of academic rigor, industry acumen, and AI expertise will propel our mission to revolutionize wellness through data-driven, evidence-based innovations. His leadership will not only elevate our research capabilities but also inspire confidence among investors, regulators, and customers as we pioneer the future of personalized health."
"I am excited to join Fifty1 AI Labs at this pivotal moment in AI-enabled health research," said Dr. Joel Gagnier. "By combining cutting-edge clinical epidemiology with machine learning, we can unlock precise, reproducible insights into wellness interventions, from peptides to pain management. I look forward to driving scientific excellence that translates into real-world impact for individuals seeking optimized health outcomes."
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is revolutionizing drug discovery by leveraging AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing, the scalability of transportability frameworks, and the ability of Fifty1 AI Labs' platform to transform oncology and global health outcomes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of partnerships and projects, the efficacy and safety of repurposed treatments, regulatory approvals, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
Who was appointed Chief Science Officer at Fifty1 Labs (FITY) on October 9, 2025?
How does Dr. Joel Gagnier's background affect Fifty1 Labs' research credibility for FITY investors?
What scientific areas will the new CSO focus on at Fifty1 Labs (FITY)?
Will the appointment of Dr. Gagnier likely help Fifty1 Labs (FITY) attract partners and funding?
What measurable credentials did Fifty1 Labs cite for Dr. Gagnier in the October 9, 2025 announcement?
